Company profile: Biocartis
1.1 - Company Overview
Company description
- Provider of a diagnostics technology platform for multiplexed detection of bio‑analytes, focused on integrated molecular and immunodiagnostics via a proprietary micro‑technology platform. Products include the Idylla fully automated sample‑to‑result real‑time PCR system for molecular diagnostics from various biological samples, and assays such as APIS ESR1, Idylla BRAF, GeneFusion (research use), ctEGFR, and NRAS‑BRAF‑EGFR S492R.
Products and services
- Idylla Platform: Fully automated, sample-to-result real-time PCR system that delivers molecular information from various biological samples for multiplexed detection on a diagnostics platform
- Idylla ctEGFR Mutation Assay: Plasma-based assay determining EGFR mutation status using plasma samples, covering 49 mutations across four exons to support molecular diagnostics
- Idylla NRAS-BRAF-EGFR S492R Mutation Assay: Multi-gene assay covering mutations in NRAS, BRAF, and EGFR S492R, requiring minimal sample size for testing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biocartis
Hexagon Bio
HQ: United States
Website
- Description: Provider of data-driven biotech solutions developing targeted small molecule therapeutics, including drug-target prediction via the TICker algorithm to identify microbial secondary metabolites that inhibit cancer-related proteins; DNA sequencing to build the world's largest database of microbial genomes and metabolites; compound production via the HEx platform using heterologous expression; and ADC payloads from natural products for oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hexagon Bio company profile →
Centogene
HQ: Germany
Website
- Description: Provider of methods and technology for human genetics analysis, delivering genetic diagnostic analyses of rare inherited diseases and transforming global genetic data into medical decisions to create broader awareness for patients of all ethnicities around the world.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centogene company profile →
GenArraytion
HQ: United States
Website
- Description: Provider of medical diagnostics products and services for tick- and mosquito-borne disease and surveillance, epidemiology and source tracking, food and water testing, biodefense and environmental monitoring, including MultiFLEX Bioassays and Sniper Sequencing genotyping services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenArraytion company profile →
Azitra
HQ: United States
Website
- Description: Provider of microbiome-based dermatology therapeutics and consumer products, offering bioengineered live biotherapeutic candidates ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor-associated rash, and protein candidate ATR-01 for ichthyosis vulgaris; and a microbiome dermatology platform to develop products for skin disease treatment and skin appearance improvement; plus topical ointments and creams for dryness, redness, flakiness, and inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Azitra company profile →
GreenLight Biosciences
HQ: United States
Website
- Description: Provider of RNA-based solutions for agriculture and human health, offering a proprietary platform to produce RNA at scale cost-effectively and products targeting pests and diseases without harming beneficial insects, including Varroa mite control for honeybees and Calantha, an EPA-approved RNA product for Colorado Potato Beetle control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GreenLight Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biocartis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biocartis
2.2 - Growth funds investing in similar companies to Biocartis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biocartis
4.2 - Public trading comparable groups for Biocartis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →